What's Going On With Tempus AI Shares Thursday?

Comments
Loading...
Zinger Key Points

Tempus AI, Inc. TEM stock is trading higher on Thursday after the company announced a collaboration with the Institute for Follicular Lymphoma Innovation (IFLI).

What To Know: The collaboration aims to advance targeted therapy development for follicular lymphoma by creating a real-world multimodal data library within Tempus’ data analytics platform. The collaboration will initially focus on generating data for POD24 patients who experience disease progression within 24 months of treatment.

This resource will enable researchers to generate AI-driven insights that could accelerate treatment progress and improve patient outcomes.

What Else: Tempus is expected to report earnings for the 2024 fiscal-year fourth-quarter on February 24 after the market closes. Analysts’ estimate a loss of 20 cents per share and revenue of $203.12 million.

Related Link: CyberArk Q4 Revenue Surges 41%, Subscription And Strong ARR Clock Strong Growth

TEM Price Action: At the time of writing, Tempus shares are trading 14.5% higher at $84.60, according to data from Benzinga Pro.

Image: Courtesy of Tempus AI

TEM Logo
TEMTempus AI Inc
$40.850.99%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
-
Growth
-
Quality
-
Value
15.01
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotech companies may benefit from Tempus' data?
How will AI in healthcare evolve after this collaboration?
Does this partnership open doors for pharmaceutical investments?
What opportunities arise for health data analytics firms?
Could Tempus' growth impact emerging market stocks?
Which oncology-focused ETFs should investors consider now?
How might investors react to the upcoming earnings report?
What are the implications for healthcare AI startups?
Which investors are targeting companies in lymphoma research?
How could this affect clinical trial companies?
Market News and Data brought to you by Benzinga APIs

Posted In: